Cargando…

Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients

Hypertension (HT) is the common adverse event associated with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKI). The present study was performed to identify the predictive factors of TKI-induced HT and to determine the classes of antihypertensive agents (AHTA) that d...

Descripción completa

Detalles Bibliográficos
Autores principales: IZUMI, KOUJI, ITAI, SHINGO, TAKAHASHI, YOSHIKO, MAOLAKE, AERKEN, NAMIKI, MIKIO
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063571/
https://www.ncbi.nlm.nih.gov/pubmed/24959266
http://dx.doi.org/10.3892/ol.2014.2060
_version_ 1782321811606732800
author IZUMI, KOUJI
ITAI, SHINGO
TAKAHASHI, YOSHIKO
MAOLAKE, AERKEN
NAMIKI, MIKIO
author_facet IZUMI, KOUJI
ITAI, SHINGO
TAKAHASHI, YOSHIKO
MAOLAKE, AERKEN
NAMIKI, MIKIO
author_sort IZUMI, KOUJI
collection PubMed
description Hypertension (HT) is the common adverse event associated with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKI). The present study was performed to identify the predictive factors of TKI-induced HT and to determine the classes of antihypertensive agents (AHTA) that demonstrate optimal efficacy against this type of HT. The charts of 50 cases of patients that had received VEGFR-TKI treatment were retrospectively examined. The association between patient background and TKI-induced HT, and the effect of administering AHTA were analyzed. High systolic blood pressure at baseline was identified to be a predictive factor for HT. In addition, there was no difference observed between calcium channel blockers (CCBs) and angiotensin receptor II blockers (ARBs) as first-line AHTA for the control of HT. The findings of the present study may aid with predicting the onset of TKI-induced HT, as well as for its management via the primary use of either CCBs or ARBs.
format Online
Article
Text
id pubmed-4063571
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-40635712014-06-23 Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients IZUMI, KOUJI ITAI, SHINGO TAKAHASHI, YOSHIKO MAOLAKE, AERKEN NAMIKI, MIKIO Oncol Lett Articles Hypertension (HT) is the common adverse event associated with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKI). The present study was performed to identify the predictive factors of TKI-induced HT and to determine the classes of antihypertensive agents (AHTA) that demonstrate optimal efficacy against this type of HT. The charts of 50 cases of patients that had received VEGFR-TKI treatment were retrospectively examined. The association between patient background and TKI-induced HT, and the effect of administering AHTA were analyzed. High systolic blood pressure at baseline was identified to be a predictive factor for HT. In addition, there was no difference observed between calcium channel blockers (CCBs) and angiotensin receptor II blockers (ARBs) as first-line AHTA for the control of HT. The findings of the present study may aid with predicting the onset of TKI-induced HT, as well as for its management via the primary use of either CCBs or ARBs. D.A. Spandidos 2014-07 2014-04-11 /pmc/articles/PMC4063571/ /pubmed/24959266 http://dx.doi.org/10.3892/ol.2014.2060 Text en Copyright © 2014, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
IZUMI, KOUJI
ITAI, SHINGO
TAKAHASHI, YOSHIKO
MAOLAKE, AERKEN
NAMIKI, MIKIO
Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients
title Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients
title_full Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients
title_fullStr Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients
title_full_unstemmed Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients
title_short Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients
title_sort predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063571/
https://www.ncbi.nlm.nih.gov/pubmed/24959266
http://dx.doi.org/10.3892/ol.2014.2060
work_keys_str_mv AT izumikouji predictivefactorandantihypertensiveusageoftyrosinekinaseinhibitorinducedhypertensioninkidneycancerpatients
AT itaishingo predictivefactorandantihypertensiveusageoftyrosinekinaseinhibitorinducedhypertensioninkidneycancerpatients
AT takahashiyoshiko predictivefactorandantihypertensiveusageoftyrosinekinaseinhibitorinducedhypertensioninkidneycancerpatients
AT maolakeaerken predictivefactorandantihypertensiveusageoftyrosinekinaseinhibitorinducedhypertensioninkidneycancerpatients
AT namikimikio predictivefactorandantihypertensiveusageoftyrosinekinaseinhibitorinducedhypertensioninkidneycancerpatients